Boxer Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Boxer Capital’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,732,571	Closed	-$17.8M	–	38
2024 Q3	$17.8M	Hold	1,732,571	–	–	0.87%	31
2024 Q2	$12.2M	Hold	1,732,571	–	–	0.65%	39
2024 Q1	$23.8M	Hold	1,732,571	–	–	1.18%	27
2023 Q4	$15.9M	Hold	1,732,571	–	–	0.79%	31
2023 Q3	$10.5M	Hold	1,732,571	–	–	0.56%	40
2023 Q2	$13.4M	Buy	1,732,571 +678,571	+64%	+$3.85M	0.62%	42
2023 Q1	$6.01M	Hold	1,054,000	–	–	0.3%	46
2022 Q4	$7.36M	Hold	1,054,000	–	–	0.39%	44
2022 Q3	$3.37M	Hold	1,054,000	–	–	0.19%	62
2022 Q2	$4.72M	Hold	1,054,000	–	–	0.3%	55
2022 Q1	$5.63M	Buy	1,054,000 +854,000	+427%	+$7.69M	0.29%	51
2021 Q4	$2.94M	Hold	200,000	–	–	0.11%	65
2021 Q3	$4.18M	Hold	200,000	–	–	0.15%	75
2021 Q2	$3.54M	Hold	200,000	–	–	0.12%	86
2021 Q1	$4.9M	Hold	200,000	–	–	0.17%	72
2020 Q4	$6.77M	Buy	+200,000	New	+$5.74M	0.22%	62

Other funds holding ORIC

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital's ORIC Position: Q4 2024 in Review

Boxer Capital sold out of Oric Pharmaceuticals (ORIC) in Q4 2024, closing a stake of 1,732,571 shares — an estimated $17.8M sold.

Boxer Capital first reported a position in ORIC in Q4 2020 and held it in 16 quarters. The position peaked at $23.8M in Q1 2024. 129 funds tracked by Wall St. Rank hold ORIC as of Q4 2024.

Boxer Capital reported no remaining Oric Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 1,732,571 Oric Pharmaceuticals shares in Q4 2024, an estimated $17.8M.
Boxer Capital first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 16 quarters.
Boxer Capital's Oric Pharmaceuticals position peaked at $23.8M in Q1 2024.
129 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.